CKD; calcium; hyperparathyroidism; phosphataemia; vitamin D
Abstract :
[en] Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary hyperparathyroidism (SHPT), to low bone turnover. The present article summarizes the important subjects that were covered during 'The Parathyroid Day in Chronic Kidney Disease' CME course organized in Paris in September 2017. It includes the latest insights on parathyroid gland growth, parathyroid hormone (PTH) synthesis, secretion and regulation by the calcium-sensing receptor, vitamin D receptor and fibroblast growth factor 23 (FGF23)-Klotho axis, as well as on parathyroid glands imaging. The skeletal action of PTH in early CKD stages to the steadily increasing activation of the often downregulated PTH receptor type 1 has been critically reviewed, emphasizing that therapeutic strategies to decrease PTH levels at these stages might not be recommended. The effects of PTH on the central nervous system, in particular cognitive functions, and on the cardiovascular system are revised, and the reliability and exchangeability of second- and third-generation PTH immunoassays discussed. The article also reviews the different circulating biomarkers used for the diagnosis and monitoring of CKD-MBD, including PTH and alkaline phosphatases isoforms. Moreover, it presents an update on the control of SHPT by vitamin D compounds, old and new calcimimetics, and parathyroidectomy. Finally, it covers the latest insights on the persistence and de novo occurrence of SHPT in renal transplant recipients.
Disciplines :
Urology & nephrology Laboratory medicine & medical technology
Author, co-author :
Urena-Torres, Pablo A.
Vervloet, Marc
Mazzaferro, Sandro
Oury, Franck
Brandenburg, Vincent
Bover, Jordi
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Ketteler M, Block GA, Evenepoel P et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What's changed and why it matters. Kidney Int 2017; 92: 26-36
Drueke TB. Hyperparathyroidism in chronic kidney disease. In: De Groot LJ, Chrousos G, Dungan K et al. (eds). Endotext. South Dartmouth, MA: MDText.com, Inc., 2000
Sela-Brown A, Naveh-Many T, Silver J. Transcriptional and post-transcriptional regulation of PTH gene expression by Vitamin D, calcium and phosphate. Miner Electrolyte Metab 1999; 25: 342-344
Shilo V, Mor-Yosef Levi I, Abel R et al. Let-7 and MicroRNA- 148 regulate parathyroid hormone levels in secondary hyperparathyroidism. J Am Soc Nephrol 2017; 28: 2353-2363
Volovelsky O, Cohen G, Kenig A et al. Phosphorylation of ribosomal protein S6 mediates mammalian target of rapamycin complex 1-induced parathyroid cell proliferation in secondary hyperparathyroidism. J Am Soc Nephrol 2016; 27: 1091-1101
Zhang P, Duchambon P, Gogusev J et al. Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 2000; 57: 437-445
Arnold A, Brown MF, Ureña P et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-2053
Imanishi Y, Tahara H, Palanisamy N et al. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 2002; 13: 1490-1498
Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580
Massy ZA, Hénaut L, Larsson TE et al. Calcium-sensing receptor activation in chronic kidney disease: Effects beyond parathyroid hormone control. Semin Nephrol 2014; 34: 648-659
Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
Hénaut L, Boudot C, Massy ZA et al. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: Mechanisms of action. Cardiovasc Res 2014; 101: 256-265
Evenepoel P, Bover J, Urena Torres P. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 2016; 90: 1184-1190
Ureña P, Kong XF, Abou-Samra AB et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 1993; 133: 617-623
Usdin TB, Bonner TI, Harta G et al. Distribution of parathyroid hormone-2 receptor messenger ribonucleic acid in rat. Endocrinology 1996; 137: 4285-4297
Bergwitz C, Klein P, Kohno H et al. Identification, functional characterization, and developmental expression of two nonallelic parathyroid hormone (PTH)/PTH-related peptide receptor isoforms in Xenopus laevis (Daudin). Endocrinology 1998; 139: 723-732
Ureña P, Iida-Klein A, Kong XF et al. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells. Endocrinology 1994; 134: 451-456
Massy Z, Drueke T. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. J Nephrol 2017; 30: 629-634
Vervloet MG, Massy ZA, Brandenburg VM et al. Bone: A new endocrine organ at the heart of chronic kidney disease and mineral disorders. Lancet Diabetes Endocrinol 2014; 2: 427-436
Olauson H, Lindberg K, Amin R et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet 2013; 9: E1003975
Ott SM. Bone cells, sclerostin, and FGF23: What's bred in the bone will come out in the flesh. Kidney Int 2015; 87: 499-501
Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238
Avci HX, Lebrun C, Wehrle R et al. Thyroid hormone triggers the developmental loss of axonal regenerative capacity via thyroid hormone receptor alpha1 and kruppel-like factor 9 in Purkinje cells. Proc Natl Acad Sci USA 2012; 109: 14206-14211
Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 2008; 58: 708-719
De la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. BiochemPharmacol 2014; 88: 548-559
Dou JT, Chen M, Dufour F et al. Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn Mem 2005; 12: 646-655
Feng L, Li AP, Wang MP et al. Plasticity at axon initial segment of hippocampal CA3 neurons in rat after status epilepticus induced by lithium-pilocarpine. Acta Neurochir (Wien) 2013; 155: 2373-2380; discussion 2380
Juntti SA, Tollkuhn J, Wu MV et al. The androgen receptor governs the execution, but not programming, of male sexual and territorial behaviors. Neuron 2010; 66: 260-272
Liston C, Cichon JM, Jeanneteau F et al. Circadian glucocorticoid oscillations promote learning-dependent synapse formation and maintenance. Nat Neurosci 2013; 16: 698-705
Oury F, Khrimian L, Denny CA et al. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell 2013; 155: 228-241
Tyzio R, Cossart R, Khalilov I et al. Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the fetal brain during delivery. Science 2006; 314: 1788-1792
Villeda SA, Luo J, Mosher KI et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477: 90-94
Villeda SA, Plambeck KE, Middeldorp J et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 2014; 20: 659-663
Aslan D, Andersen MD, Gede LB et al. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest 2012; 72: 14-22
Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. Annu Rev Cell Dev Biol 2009; 25: 629-648
Dotzenrath CME, Kaetsch AK, Pfingsten H et al. Neuropsychiatric and cognitive changes after surgery for primary hyperparathyroidism. World J Surg 2006; 30: 680-685
Numann PJ, Torppa AJ, Blumetti AE. Neuropsychologic deficits associated with primary hyperparathyroidism. Surgery 1984; 96: 1119-1123
Walker MD, McMahon DJ, Inabnet WB et al. Neuropsychological features in primary hyperparathyroidism: A prospective study. J Clin EndocrinolMetab 2009; 94: 1951-1958
Chiang CY, Andrewes DG, Anderson D et al. A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patients. Clin Endocrinol (Oxf) 2005; 62: 99-104
Chou F-F, Chen J-B, Hsieh K-C et al. Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism. Surgery 2008; 143: 526-532
Gilli P, De Bastiani P. Cognitive function and regular dialysis treatment. Clin Nephrol 1983; 19: 188-192
Schram MT, Trompet S, Kamper AM et al. Serum calcium and cognitive function in old age. J Am Geriatr Soc 2007; 55: 1786-1792
Bühler G, Balabanova S, Milowski S et al. Detection of immunoreactive parathyroid hormone-related protein in human cerebrospinal fluid. Exp Clin Endocrinol Diabetes 1997; 105: 336-340
Joborn C, Hetta J, Niklasson F et al. Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism. Psychoneuroendocrinology 1991; 16: 311-322
Lourida I, Thompson-Coon J, Dickens CM et al. Parathyroid hormone, cognitive function and dementia: A systematic review. PLoS One 2015; 10: E0127574
Usdin TB, Gruber C, Bonner TI. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem 1995; 270: 15455-15458
Weaver DR, Deeds JD, Lee K et al. Localization of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor mRNAs in rat brain. Brain Res Mol Brain Res 1995; 28: 296-310
Weir EC, Brines ML, Ikeda K et al. Parathyroid hormonerelated peptide gene is expressed in the mammalian central nervous system. Proc Natl Acad Sci USA 1990; 87: 108-112
Lepage R, Roy L, Brossard JH et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44: 805-809
Souberbielle J-C, Boutten A, Carlier M-C et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006; 70: 345-350
Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2006; 366: 81-89
Bilezikian JP, Brandi ML, Eastell R et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. J Clin EndocrinolMetab 2014; 99: 3561-3569
Cavalier E, Delanaye P, Vranken L, et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: Importance of the reference (normal) values. Nephrol Dial Transplant 2012; 27: 1950-1956
Tepel M, Armbruster FP, Grön HJ et al. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab 2013; 98: 4744-4751
Seiler-Mussler S, Limbach AS, Emrich IE et al. Association of nonoxidized parathyroid hormone with cardiovascular and kidney disease outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2018
Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156
Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366
Wakasugi M, Kazama JJ, Taniguchi M et al. Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 2013; 31: 315-321
Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121
Stehman-Breen CO, Sherrard DJ, Alem AM et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 2200-2205
Kazama JJ, Iwasaki Y, Fukagawa M. Uremic osteoporosis. Kidney Int Suppl (2011) 2013; 3: 446-450
Kazama JJ, Matsuo K, Iwasaki Y et al. Chronic kidney disease and bone metabolism. J Bone Miner Metab 2015; 33: 245-252
Maruyama Y, Taniguchi M, Kazama JJ et al. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol Dial Transplant 2014; 29: 1532-1538
Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
Lau WL, Kalantar-Zadeh K, Kovesdy CP et al. Alkaline phosphatase: Better than PTH as a marker of cardiovascular and bone disease? Hemodial Int 2014; 18: 720-724
Pilz S, Tomaschitz A, Drechsler C et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31: 1591-1598
Vaidya A, Brown JM, Williams JS. The renin-angiotensinaldosterone system and calcium-regulatory hormones. J Hum Hypertens 2015; 29: 515-521
McMahon DJ, Carrelli A, Palmeri N et al. Effect of parathyroidectomy upon left ventricular mass in primary hyperparathyroidism: A meta-analysis. J Clin Endocrinol Metab 2015; 100: 4399-4407
Moe SM, Chertow GM, Parfrey PS et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Circulation 2015; 132: 27-39
Lehner S, Todica A, Vanchev Y et al. In vivo monitoring of parathyroid hormone treatment after myocardial infarction in mice with [(68)Ga]Annexin A5 and [(18)F]Fluorodeoxyglucose positron emission tomography. Mol Imaging 2014; 13: 7290201400035
Brunner S, Weinberger T, Huber BC et al. The cardioprotective effects of parathyroid hormone are independent of endogenous granulocyte-colony stimulating factor release. Cardiovasc Res 2012; 93: 330-339
KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;113: S1-S130
Agarwal R, Georgianos PI. Con: Nutritional Vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2016; 31: 706-713
Goldsmith DJ. Pro: Should we correct Vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of Vitamin D or just treat them with active Vitamin D forms? Nephrol Dial Transplant 2016; 31: 698-705
Sprague SM, Crawford PW, Melnick JZ et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol 2016; 44: 316-325
Sprague SM, Strugnell SA. Bishop CW. Extended-release calcifediol (Rayaldee) for secondary hyperparathyroidism. Med Lett Drugs Ther 2017; 59: 36-37
Block GA, Martin KJ, De Francisco ALM et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
Behets GJ, Spasovski G, Sterling LR et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 87: 846-856
Chertow GM, Parfrey PS. Cinacalcet for cardiovascular disease in patients undergoing dialysis. N Engl J Med 2013; 368: 1844-1845
Raggi P, Bellasi A, Gamboa C et al. All-cause mortality in hemodialysis patients with heart valve calcification. Clin J Am Soc Nephrol 2011; 6: 1990-1995
Investigators TET. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 357: 2482-2494
Block GA, Bushinsky DA, Cunningham J et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: Two randomized clinical trials. JAMA 2017; 317: 146-155
Block GA, Bushinsky DA, Cheng S et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial. JAMA 2017; 317: 156-164
Tentori F, Wang M, Bieber BA et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study. Clin J Am Soc Nephrol 2015; 10: 98-109
Kim SM, Long J, Montez-Rath ME et al. Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States. Clin J Am Soc Nephrol 2016; 11: 1260-1267
Wetmore JB, Liu J, Do TP et al. Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. Nephrol Dial Transplant 2016; 31: 103-111
Mazzaferro S, Pasquali M, Farcomeni A et al. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant 2008; 23: 2319-2323
Hernandes FR, Canziani MEF, Barreto FC et al. The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study. PLoS One 2017; 12: E0174811
Isaksson E, Ivarsson K, Akaberi S et al. The effect of parathyroidectomy on risk of hip fracture in secondary hyperparathyroidism. World J Surg 2017; 41: 2304-2311
Ishani A, Liu J, Wetmore JB et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 2015; 10: 90-97
Komaba H, Taniguchi M, Wada A et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 88: 350-359
Scialla JJ, Wolf M. When there will never be a randomized controlled trial. Kidney Int 2015; 88: 220-222
Zhang L, Xing C, Shen C et al. Diagnostic accuracy study of intraoperative and perioperative serum intact PTH level for successful parathyroidectomy in 501 secondary hyperparathyroidism patients. Sci Rep 2016; 6: 26841
Konturek A, Barczynski M, Stopa M et al. Subtotal parathyroidectomy for secondary renal hyperparathyroidism: A 20- year surgical outcome study. Langenbecks Arch Surg 2016; 401: 965-974
Vulpio C, Bossola M, De Gaetano A et al. Parathyroid gland ultrasound patterns and biochemical findings after oneyear cinacalcet treatment for advanced secondary hyperparathyroidism. Ther Apher Dial 2010; 14: 178-185
HindiéE, Ureña P, Jeanguillaume C et al. Preoperative imaging of parathyroid glands with technetium-99mlabelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet 1999; 353: 2200-2204
Karipineni F, Sahli Z, Somervell H et al. Are preoperative sestamibi scans useful for identifying ectopic parathyroid glands in patients with expected multigland parathyroid disease? Surgery 2018; 163: 35-41
HindiéE, Ugur O, Fuster D et al. 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging 2009; 36: 1201-1216
Krakauer M, Wieslander B, Myschetzky PS et al. A prospective comparative study of parathyroid dual-phase scintigraphy, dual-isotope subtraction scintigraphy, 4D-CT, and ultrasonography in primary hyperparathyroidism. Clin Nucl Med 2016; 41: 93-100
Fuster D, Ybarra J, Ortin J et al. Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy. Eur J Nucl Med Mol Imaging 2006; 33: 467-473
HindiéE, Urena P, Melliere D et al. Technetium-99m-sestamibi and iodine-123 subtraction scanning in primary and secondary hyperparathyroidism. Adv Nephrol Necker Hosp 1999; 29: 221-240
HindiéE, Zanotti-Fregonara P, Just P-A et al. Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. Eur J Nucl Med Mol Imaging 2010; 37: 623-634
Hindie E, Zanotti-Fregonara P, Tabarin A et al. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J Nucl Med 2015; 56: 737-744
Michaud L, Balogova S, Burgess A et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: Influence of thyroid anomalies. Medicine (Baltimore) 2015; 94: E1701
Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol 2013; 33: 191-203
Evenepoel P, Bammens B, Claes K et al. Measuring total blood calciumdisplays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol 2010; 5: 2085-2092
Evenepoel P, Naesens M, Claes K et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007; 7: 1193-1200
van Londen M, Aarts BM, Deetman PE et al. Post-transplant hypophosphatemia and the risk of death-censored graft failure and mortality after kidney transplantation. Clin J Am Soc Nephrol 2017; 12: 1301-1310
Iyer SP, Nikkel LE, Nishiyama KK et al. Kidney transplantation with early corticosteroid withdrawal: Paradoxical effects at the central and peripheral skeleton. J Am Soc Nephrol 2014; 25: 1331-1341
Giannini S, Sella S, Silva Netto F et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: Role of calcium-sensing receptor polymorphisms and Vitamin D deficiency. J BoneMinerRes 2010; 25: 841-848
Perrin P, Caillard S, Javier RM et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 2013; 13: 2653-2663
Evenepoel P, Lerut E, Naesens M et al. Localization, etiology and impact of calcium phosphate deposits in renal allografts. Am J Transplant 2009; 9: 2470-2478
Cruzado JM, Moreno P, Torregrosa JV et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol 2016; 27: 2487-2494
Trillini M, Cortinovis M, Ruggenenti P et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol 2015; 26: 1205-1214
Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004; 19: 1281-1287
Evenepoel P, Cavalier E, D'Haese PC. Biomarkers predicting bone turnover in the setting of CKD. Curr Osteoporos Rep 2017; 15: 178-186
Evenepoel P, Behets GJ, Viaene L et al. Bone histomorphometry in De novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int 2017; 91: 469-476